← All trials
NCT05187377
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2022
- Primary completion
- Jul 1, 2024
- Completion date
- Jul 1, 2024
- First posted
- Jan 11, 2022
- Last posted
- Jul 26, 2022
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.